- Home
- LNKB vs ADAP Comparison
LNKB vs ADAP Comparison
Compare LNKB & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- ADAP
- Stock Information
- Founded
- LNKB 2018
- ADAP 2008
- Country
- LNKB United States
- ADAP United Kingdom
- Employees
- LNKB N/A
- ADAP N/A
- Industry
- LNKB
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- LNKB
- ADAP Health Care
- Exchange
- LNKB Nasdaq
- ADAP Nasdaq
- Market Cap
- LNKB 256.4M
- ADAP 75.5M
- IPO Year
- LNKB N/A
- ADAP 2015
- Fundamental
- Price
- LNKB $7.67
- ADAP $0.25
- Analyst Decision
- LNKB Strong Buy
- ADAP Buy
- Analyst Count
- LNKB 1
- ADAP 6
- Target Price
- LNKB $9.00
- ADAP $1.35
- AVG Volume (30 Days)
- LNKB 65.4K
- ADAP 681.6K
- Earning Date
- LNKB 07-28-2025
- ADAP 08-11-2025
- Dividend Yield
- LNKB 3.91%
- ADAP N/A
- EPS Growth
- LNKB N/A
- ADAP N/A
- EPS
- LNKB 0.97
- ADAP N/A
- Revenue
- LNKB $120,786,000.00
- ADAP $179,639,000.00
- Revenue This Year
- LNKB $21.23
- ADAP N/A
- Revenue Next Year
- LNKB N/A
- ADAP $35.48
- P/E Ratio
- LNKB $7.93
- ADAP N/A
- Revenue Growth
- LNKB 135.60
- ADAP 878.53
- 52 Week Low
- LNKB $6.00
- ADAP $0.20
- 52 Week High
- LNKB $7.98
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- LNKB 66.63
- ADAP 45.94
- Support Level
- LNKB $6.67
- ADAP $0.23
- Resistance Level
- LNKB $7.70
- ADAP $0.25
- Average True Range (ATR)
- LNKB 0.25
- ADAP 0.02
- MACD
- LNKB 0.08
- ADAP -0.00
- Stochastic Oscillator
- LNKB 96.39
- ADAP 54.55
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.